# Bioequivalence Study for Acarbose / Metformin FDC

> **NCT01728740** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 40 (actual)

## Conditions studied

- Diabetes Mellitus, Type II

## Interventions

- **DRUG:** Acarbose/Metformin FDC (BAY81-9783)
- **DRUG:** Acarbose (Glucobay, BAYG5421)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01728740
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728740, "Bioequivalence Study for Acarbose / Metformin FDC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01728740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*